Impax Asset Management Group
GILD icon

Impax Asset Management Group’s Gilead Sciences GILD Stock Holding History

Impax Asset Management Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.3M Buy
224,260
+13,447
+6% +$1.77M 0.18% 86
2026
Q1 		$29.4M Sell
210,813
-85,752
-29% -$12M 0.2% 86
2025
Q4 		$36.4M Buy
296,565
+19,894
+7% +$2.42M 0.23% 85
2025
Q3 		$30.7M Sell
276,671
-17,942
-6% -$2.04M 0.18% 86
2025
Q2 		$32.7M Buy
294,613
+10,607
+4% +$1.13M 0.19% 89
2025
Q1 		$31.8M Sell
284,006
-96,564
-25% -$9.96M 0.19% 91
2024
Q4 		$35.2M Buy
380,570
+212,828
+127% +$19.2M 0.16% 98
2024
Q3 		$14.1M Sell
167,742
-7,979
-5% -$609K 0.06% 136
2024
Q2 		$12.1M Buy
175,721
+49,920
+40% +$3.33M 0.05% 147
2024
Q1 		$9.21M Sell
125,801
-37,289
-23% -$2.87M 0.04% 178
2023
Q4 		$13.2M Sell
163,090
-327
-0.2% -$25.4K 0.05% 152
2023
Q3 		$12.2M Buy
163,417
+53,704
+49% +$4.13M 0.05% 141
2023
Q2 		$8.46M Buy
109,713
+668
+0.6% +$53.3K 0.03% 177
2023
Q1 		$9.05M Buy
109,045
+69,533
+176% +$5.76M 0.04% 161
2022
Q4 		$3.39M Buy
39,512
+2
+0% +$158 0.02% 200
2022
Q3 		$2.44M Sell
39,510
-887
-2% -$55.9K 0.01% 215
2022
Q2 		$2.5M Sell
40,397
-4,047
-9% -$251K 0.01% 220
2022
Q1 		$2.64M Buy
44,444
+2,986
+7% +$191K 0.01% 229
2021
Q4 		$3.01M Buy
41,458
+1,257
+3% +$86.6K 0.01% 220
2021
Q3 		$2.81M Buy
40,201
+149
+0.4% +$10.5K 0.01% 225
2021
Q2 		$2.76M Sell
40,052
-17
-0% -$1.14K 0.01% 225
2021
Q1 		$2.59M Buy
40,069
+1,996
+5% +$129K 0.01% 223
2020
Q4 		$2.22M Buy
38,073
+3,189
+9% +$192K 0.01% 200
2020
Q3 		$2.2M Buy
34,884
+1,067
+3% +$74K 0.02% 194
2020
Q2 		$2.6M Buy
33,817
+874
+3% +$67K 0.03% 191
2020
Q1 		$2.46M Buy
32,943
+5,361
+19% +$370K 0.03% 183
2019
Q4 		$1.79M Buy
+27,582
New +$1.8M 0.02% 199

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Impax Asset Management Group's GILD Position: Q2 2026 in Review

Impax Asset Management Group increased its Gilead Sciences (GILD) stake by 6.4% in Q2 2026, buying an estimated $1.77M and bringing the position to 224,260 shares worth $28.3M. The position accounts for 0.18% of the portfolio, ranked #86.

Impax Asset Management Group first reported a position in GILD in Q4 2019 and has held it in 27 quarters since. The position peaked at $36.4M in Q4 2025. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Impax Asset Management Group held 224,260 shares of Gilead Sciences worth $28.3M as of Q2 2026.
  • Impax Asset Management Group bought 13,447 Gilead Sciences shares in Q2 2026, an estimated $1.77M.
  • Gilead Sciences made up 0.18% of Impax Asset Management Group's portfolio in Q2 2026, its #86 holding.
  • Impax Asset Management Group first reported a position in Gilead Sciences in Q4 2019 and has held it in 27 quarters since.
  • Impax Asset Management Group's Gilead Sciences position peaked at $36.4M in Q4 2025.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Impax Asset Management Group's 13F filing for Q2 2026, filed 11 Aug 2026.